The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator’s choice—A subset analysis by prognostic group.
Stuart Goldberg
Research Funding - Celator
Jorge E. Cortes
Consultant or Advisory Role - Celator (U)
Research Funding - Celator
Eric Jay Feldman
Consultant or Advisory Role - Celator (U)
Research Funding - Celator
David Rizzieri
Research Funding - Celator
Hagop Kantarjian
Consultant or Advisory Role - Celator (U)
Research Funding - Celator
Sora Limor
Research Funding - Celator
Arthur Chin Louie
Employment or Leadership Position - Celator
Stock Ownership - Celator
Jonathan E. Kolitz
Consultant or Advisory Role - Celator (U)
Research Funding - Celator